主要收入构成
报告期：2023-12-31
| 主营产品构成（百万） |
| 名称 |
占总收入比例 |
收入 |
同比变化 |
成本 |
毛利率 |
同比变化 |
| 肝病治疗 |
7.57% |
656.87 |
12.96% |
117.04 |
82.18% |
-0.65% |
| 感冒发烧 |
5.86% |
508.50 |
18.42% |
194.19 |
61.81% |
10.17% |
| 抗肿瘤 |
2.19% |
190.09 |
-39.67% |
65.88 |
65.34% |
0.17% |
| 其他 |
9.36% |
812.02 |
9.50% |
312.83 |
61.47% |
-5.51% |
| 其他(补充) |
0.43% |
37.71 |
22.38% |
17.11 |
54.63% |
-2.26% |
| 心脑血管 |
60.57% |
5253.60 |
3.45% |
1316.82 |
74.93% |
2.18% |
| 医药商业小计 |
14.01% |
1215.23 |
-- |
856.23 |
29.54% |
-- |
| 总计 |
8674.01 |
| 行业收入构成（百万） |
| 名称 |
占总收入比例 |
收入 |
同比变化 |
成本 |
毛利率 |
同比变化 |
| 化学原料药 |
0.66% |
57.13 |
-19.67% |
26.87 |
52.97% |
-1.96% |
| 化学制剂药 |
13.87% |
1202.96 |
-5.30% |
234.19 |
80.53% |
1.51% |
| 其他(补充) |
0.43% |
37.71 |
22.38% |
17.11 |
54.63% |
-2.26% |
| 生物药 |
2.18% |
189.53 |
-23.47% |
88.14 |
53.49% |
-9.65% |
| 医药商业小计 |
14.01% |
1215.23 |
-14.21% |
856.23 |
29.54% |
2.29% |
| 中药 |
68.84% |
5971.46 |
7.46% |
1657.57 |
72.24% |
2.04% |
| 总计 |
8674.01 |
| 地区收入构成（百万） |
| 名称 |
占总收入比例 |
收入 |
同比变化 |
成本 |
毛利率 |
同比变化 |
| 抵消 |
-- |
-7758.11 |
-- |
-7831.96 |
-0.95% |
-- |
| 江苏省 |
4.25% |
697.91 |
-23.33% |
177.39 |
74.58% |
0.11% |
| 辽宁省 |
5.76% |
946.08 |
-2.18% |
653.22 |
30.96% |
-0.08% |
| 其他 |
1.61% |
263.89 |
17.28% |
143.48 |
45.63% |
-1.73% |
| 其他(补充) |
0.23% |
37.71 |
22.38% |
17.11 |
54.63% |
-2.26% |
| 山东省 |
1.69% |
277.87 |
-2.27% |
191.38 |
31.13% |
-1.66% |
| 陕西省 |
0.59% |
96.13 |
2.45% |
86.84 |
9.67% |
2.78% |
| 上海市 |
1.15% |
189.52 |
-23.47% |
88.13 |
53.50% |
-9.82% |
| 天津市 |
84.73% |
13923.01 |
5.40% |
9354.52 |
32.81% |
0.48% |
| 总计 |
8674.01 |
